RxDoctor Payments Data

Charlotte Lanphear

Medical · Lutherville, MDNPI 1497220826

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Eli Lilly at 45.8% of the total. 2025 is the largest year on record at $10,282, more than ten times the $483 reported in 2021. Among medical clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,075in general payments, 2019–2025

Across 338 payments — averaging $44.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$7K
  • Regeneron Healthcare Solutions, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • AbbVie$860
  • Johnson & Johnson$815
  • Novartis$729
  • plus $4K from 22 others

What the payments were for

  • Consulting fees$6,90046%
  • Food & beverage$7,46249%
  • Education$7135%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,075 in reported general payments places this provider in the 95th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$174,589
Medicare patients
473
Services billed
3,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab23$87,760
ZoryveRoflumilast14$12,121
Tretinoin57$4,994
Clobetasol Propionate63$3,056
Imiquimod48$1,856
Desonide14$819
Ketoconazole61$818
Fluocinolone Acetonide17$622
Doxycycline Hyclate31$484
Ammonium Lactate16$407
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$364
Mupirocin24$300
Triamcinolone Acetonide27$262
Nystatin16$171
Lidocaine-PrilocaineLidocaine/Prilocaine11$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$40$12,12114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 medical providers in Maryland.

Other medical in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →